Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
Doxorubicin (DOX) is a cytostatic drug with a broad spectrum of anticancer activity that has been used in oncology for over 50 years. Among many adverse effects in humans, the most dangerous is late dilated cardiomyopathy, which appears even years after completion of therapy. However, in cats, the c...
Saved in:
| Main Authors: | Szponar Jaroslaw, Gorska Agnieszka, Ostrowska-Lesko Marta, Wielgomas Bartosz, Mandziuk Slawomir |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2024-12-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/cipms-2024-0038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity
by: Zachary M. Neiman, et al.
Published: (2025-07-01) -
Anthracycline-induced cardiac toxicity: A clinical review
by: Adil Abdelhameed Abbas, et al.
Published: (2019-01-01) -
Extravascular leakage of dexrazoxane that occurred in a patient with diffuse large B-cell lymphoma: a case report
by: Nao Wakamiya, et al.
Published: (2025-06-01) -
Safety Evaluation of the Combination with Dexrazoxane and Anthracyclines: A Disproportionality Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database
by: Danyi Liu, et al.
Published: (2024-12-01) -
Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b
by: Hui-Ming Chang, et al.
Published: (2025-05-01)